Navigation Links
Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
Date:5/19/2011

GREENWOOD VILLAGE, Colo., May 19, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq Capital Market: AMPE) ("Ampio" or the "Company"), a company focused on new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that its common stock will commence trading on the NASDAQ Capital Market under the ticker symbol "AMPE" commencing today, May 19, 2011.

Don Wingerter, the Company's CEO, said, "We are extremely excited to begin trading on the NASDAQ Capital Market – a milestone in our market exposure. With this listing, we will no longer trade on the OTC Bulletin Board. We believe this listing is an excellent opportunity to introduce new investors to Ampio and our vision for product candidates we are currently developing."

About Ampio

The Company is currently performing a phase II clinical trial for the treatment of diabetic macular edema and is evaluating the data from a recently completed phase III clinical trial for the treatment of premature ejaculation.  Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction.  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, such as changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact:
Investor Relations
Ampio Pharmaceuticals, Inc.
303-418-1000


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
2. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
3. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
4. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
5. Kaiser Permanente Recognized as a J.D. Power 2011 Customer Service Champion
6. CHAMPION Study Published in The Lancet
7. Champions CFO Resigns
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His Notoriety in New ExtenZe Spots from Inter/Media Advertising
10. Dr. Brian Boxer Wachler to be Honored With Olympic Gold Medal Bobsled Champion Steve Holcomb Alongside Apple CEO Steve Jobs, James Cameron, Dan Rather, Quincy Jones and Others at 2010 Vision Awards in Beverly Hills
11. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction ... at a time when Virginia faces an opioid epidemic. , Last ... increase of 38 percent from 2015, underscoring the need for additional addiction treatment ...
(Date:9/21/2017)... Fort Worth, TX (PRWEB) , ... September 21, ... ... top 50 senior housing operators, announces the acquisition of Isle at Kingwood Assisted ... Isle at Kingwood is an established retirement community with 55 assisted living apartments, ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... the Month, Lewis and Clark College Emeritus Professor of Education Gregory A. Smith ... co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the ... quick and easy access to essential information that offers a more comprehensive understanding ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... as one of the Best Places to Work in the Research Triangle for ... Workplace. Once nominated, a company had to meet a threshold in employee participation--a ...
Breaking Medicine News(10 mins):